WO2004000321A1 - Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis - Google Patents
Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis Download PDFInfo
- Publication number
- WO2004000321A1 WO2004000321A1 PCT/EP2002/008062 EP0208062W WO2004000321A1 WO 2004000321 A1 WO2004000321 A1 WO 2004000321A1 EP 0208062 W EP0208062 W EP 0208062W WO 2004000321 A1 WO2004000321 A1 WO 2004000321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- group
- alkyl
- oxygen
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 10
- 239000003112 inhibitor Substances 0.000 title abstract description 14
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 title description 4
- 150000004893 oxazines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 47
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 30
- 239000001257 hydrogen Substances 0.000 claims abstract description 30
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000001301 oxygen Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 229910052736 halogen Chemical group 0.000 claims abstract description 23
- 150000002367 halogens Chemical group 0.000 claims abstract description 23
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 16
- 125000003118 aryl group Chemical group 0.000 claims abstract description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 15
- 102000005741 Metalloproteases Human genes 0.000 claims abstract description 12
- 108010006035 Metalloproteases Proteins 0.000 claims abstract description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 11
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract description 7
- 229940126601 medicinal product Drugs 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- -1 hydroxy, cyano, tetrazolyl Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000005864 Sulphur Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 201000008482 osteoarthritis Diseases 0.000 claims description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000028169 periodontal disease Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 229910006124 SOCl2 Inorganic materials 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000003939 benzylamines Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 150000002431 hydrogen Chemical group 0.000 abstract description 3
- 230000003287 optical effect Effects 0.000 abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 9
- 238000001816 cooling Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229940124761 MMP inhibitor Drugs 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 0 **(C(I)=*)C(C1=C(*)I=*C(C#N)=*1)=O Chemical compound **(C(I)=*)C(C1=C(*)I=*C(C#N)=*1)=O 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- BCEQKAQCUWUNML-UHFFFAOYSA-N 4-hydroxybenzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC=C(O)C(C(O)=O)=C1 BCEQKAQCUWUNML-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108700010340 Leishmanolysins Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102000036436 Metzincins Human genes 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VEVHNOJSQMKHGD-UHFFFAOYSA-N 4-[[2,4-dioxo-6-(3-phenylprop-1-ynyl)-1,3-benzothiazin-3-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C(=O)C2=CC(C#CCC=3C=CC=CC=3)=CC=C2SC1=O VEVHNOJSQMKHGD-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UINIBOQGXIFOQN-UHFFFAOYSA-N 5-bromo-2-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1S UINIBOQGXIFOQN-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- IBTNPBFVLBUACF-UHFFFAOYSA-N NC(c(cc1C(N)=O)ccc1N)=O Chemical compound NC(c(cc1C(N)=O)ccc1N)=O IBTNPBFVLBUACF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- NGKSKVYWPINGLI-UHFFFAOYSA-N prop-2-ynylbenzene Chemical compound C#CCC1=CC=CC=C1 NGKSKVYWPINGLI-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- GSIBTIUXYYFCPU-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(CBr)C=C1 GSIBTIUXYYFCPU-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
Definitions
- the present invention relates to novel thiazine and oxazine derivatives which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor.
- MMP-13 matrix metalloprotease-13
- These medicinal products are useful in particular for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.
- MMPs Matrix metalloproteases
- TLMPs tissue inhibitors of metalloprotease
- MMP-13 matrix metalloprotease-13 is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.
- MMP inhibitors are known. Most of these MMP-inhibitors are not selective for a single MMP, such as those described by Montana and Baxter (2000) or by Clark et al. (2000).
- the applicant has identified novel thiazine and oxazine derivatives that are matrix metalloprotease inhibitors, and more specifically compounds that are selective MMP-13 inhibitors.
- X ⁇ , X 2 , and X 3 independently of each other, represent a nitrogen atom or a group -CR 3 in which R 3 represents a group selected from hydrogen, ( -C ⁇ alkyl, amino, mono(C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, hydroxy, ( -C 6 )alkoxy, and halogen, with the proviso that not more than two of the groups Xi, X 2 and X 3 simultaneously represent a nitrogen atom,
- G ⁇ represents an oxygen atom or a group S(O) p in which p represents an integer from 0 to 2 inclusive,
- Yi represents a group selected from oxygen, sulphur, -NH and -N(C ⁇ -C 6 )alkyl
- Y 2 represents a group selected from oxygen, sulphur, -NH and -N ⁇ -C ⁇ alkyl
- n represents an integer from 0 to 6 inclusive
- hydrocarbon chain Z 1 optionally contains one to two isolated or conjugated multiple bonds
- one of said -CR4R 5 may be replaced with a group selected from oxygen, S(O) r in which r represents an integer from 0 to 2 inclusive, -NH and -N(C ⁇ -C 6 )alkyl,
- A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles
- R ⁇ represents a group selected from :
- hydrocarbon chain Z 2 optionally contains one or two isolated or conjugated multiple bonds
- one of said -CR 9 R 10 may be replaced with a group selected from oxygen, S(O) u in which u is an integer from 0 to 2 inclusive, -NH, -N(C 1 -C 6 )alkyl, and carbonyl,
- ⁇ S B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
- the group(s) G 3 which may be identical or different independently of each other, is (are) selected from (CrC 6 )alkyl, halogen, CN, NO 2 , CF 3 , OCF 3 , -(CH 2 ) k NR ⁇ R ⁇ 2 , -N(R ⁇ )SO 2 R 12 , -N(SO 2 R u ) 2 , -OR u , -S(O) kl R lb -SO 2 -N(R ⁇ )-(CH 2 ) ⁇ ⁇ -NR 12 R 13 , -(CH 2 ) k SO 2 NR ⁇ R 12 ,
- - represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (C 1 -C 6 )alkyl group,
- - k is an integer from 0 to 3 inclusive
- - kl is an integer from 0 to 2 inclusive
- - k2 is an integer from 1 to 4 inclusive
- R ⁇ , R 12 and R 13 which may be identical or different independently of each other, are selected from hydrogen and (CrC ⁇ alkyl,
- R 15 represents a (C 3 -C 6 )cycloalkyl group
- - X 5 represents a group selected from a single bond, -CH 2 -, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C 1 -C 6 )alkyl,
- X 7 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C 1 -C 6 )alkyl,
- - k is an integer from 0 to 3 inclusive
- R 7 and R 8 which may be identical or different independently of each other, are selected from hydrogen and (CpC 6 )alkyl,
- X 8 represents a group selected from single bond, -CH 2 -, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (d-C 6 )alkyl,
- R 18 represents a group selected from phenyl, a 5- or 6-membered monocyclic, heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (C 1 -C 6 )alkyl, halogen, hydroxy and amino, and optionally, their racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts, and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H- l,3-benzothiazine)-benzoate, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzothiazine and 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzo
- the invention relates to compounds of formula (I) wherein :
- Y in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Y ⁇ represents an oxygen atom, and Y 2 represents a group -NH,
- the invention relates to compounds of formula (I) wherein :
- G 2 represents a group of formula (i/a):
- the invention relates to compounds of formula (I) wherein : • G t represents a sulphur atom,
- G 2 represents a carbon-carbon triple bond
- n represents an integer from 1 to 6 inclusive
- X ls X 2 , X 3 , Zi, A, R 1; m and R 2 are as defined in formula (I).
- the invention relates to compounds of formula (I) wherein :
- n represents an integer from 1 to 6 inclusive
- Xi, X 2 , X 3 , Zi, A, R ; m and R are as defined in formula (I).
- Z 2 represents a group -CR 9 R 10 in which R 9 and R 10 represents each a hydrogen atom, s is equal to one, and B, G 3 , and t are as defined in the compound of formula (I).
- substituent Rj that is preferred according to the invention is the group of formula (i/b):
- B represents a phenyl group
- t is equal to 0 or 1
- Preferred compounds of the invention are compounds of formula (I) wherein X represents a group -CR in which R 3 represents a hydrogen atom, X 2 represents a nitrogen atom or a group -CR in which R represents a hydrogen atom, and X 3 represents a group -CR 3 in which R 3 represents a hydrogen atom.
- preferred compounds of the invention are those compounds of formula (I) wherein Z ⁇ represents -CR R 5 in which t and R 5 represent each a hydrogen atom, and n is equal to one.
- Especially preferred compounds of the invention are compounds of formula (I) wherein A represents a group selected from phenyl and pyridyl, m is equal to zero or one, and R 2 represents a ( -C ⁇ alkoxy group or a hydrogen atom.
- Another especially preferred compounds of the invention are compound of formula (I) wherein A represents an imidazolyl group.
- the invention relates to the following compounds of formula (I) :
- optical isomers, the N-oxides, as well as the addition salts with a pharmaceutically- acceptable acid or base, of the preferred compounds form an integral part of the invention.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient an effective amount of a compound of formula (I) together with one or more pharmaceutically-acceptable excipients or carriers.
- Another embodiment of the invention concerns the use of the compound of formula (I) for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease.
- the invention also relates to a method for treating a living body afflicted with a disease involving a therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease, the said method comprising the administration of an effective amount of a compound of formula (I) to a patient in need thereof.
- a preferred method of treatment according to this invention is treatment of a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
- a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
- a preferred method of treatment according to this invention is treatment of disease selected from arthritis, osteoarthritis and rheumatoid arthritis.
- - a (C 1 -C 6 )alkyl group denotes a linear or branched group containing from 1 to 6 carbon atoms ;
- example of such groups, without implying any limitation are methyl, ethyl, propyl, isopropyl, tert-butyl, neopentyl, hexyl, - a (C 2 -C 6 )alkenyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more double bonds ; examples of such groups without implying any limitation are vinyl, allyl, 3-buten-l-yl, 2-methyl-buten-l-yl, hexenyl,
- - a (C 2 -C 6 )alkynyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more triple bonds ; examples of such groups without implying any limitation are ethynyl, propynyl, 3-butyn-l-yl, 2-methyl-butyn-l-yl, hexynyl, - a (C 1 -C 6 )alkoxy group means the alkyl group as mentioned above bound through an oxygen atom ; examples of such compounds without implying any limitation are methoxy, ethoxy, n-propyloxy, tert-butyloxy,
- a mono(C 1 -C 6 )alkylamino denotes a amino group substituted by one (d-C ⁇ alkyl group as defined hereinbefore ;
- example of such groups, without implying any limitation are methyl amino, isobutyl amino, ethylamino, a di(C 1 -C 6 )alkylamino denotes a amino group substituted by two (C 1 -C 6 )alkyl groups as defined hereinbefore, each alkyl group being identical or different ;
- example of such groups, without implying any limitation are dimethylamino, diethylamino, - an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated ;
- examples of such groups without implying any limitation are, phenyl, naph
- a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character ; examples of such groups without implying any limitation are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, adamantyl, decalinyl, norbornyl, a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen,
- a bicycle denotes two fused-monocycle or two bridged-monocycle
- a trihalogeno(C -C 6 )alkyl group denotes an alkyl group as defined above which contains a trihalogeno group
- examples of such groups without implying any limitation are trifluoromethyl, 2,2,2-trifluoroethyl
- a (CrC 7 )acyl group denotes an alkyl group or an aryl group as defined above bound through a carbonyl group
- examples of such groups without implying any limitation are acetyl, ethylcarbonyl, benzoyl, a multiple bond denotes double bond or triple bond
- a halogen atom means fluoro, chloro, bromo or iodo
- optical isomers refer to racemates, enantiomers and diastereoisomers.
- the invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I).
- Pharmaceutically acceptable acids mean non-toxic mineral or organic acids. Among those there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, nitric acid, citric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, benzoic acid, toluenesulfonic acid, etc...
- Pharmaceutically acceptable bases mean non-toxic mineral or organic bases. Among those, there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, calcium hydroxide, triethylamine, tert-butylamine, dibenzylethylenediamine, piperidine, pyrrolidine, benzylamine, quaternary ammonium hydroxides etc...
- the invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
- compounds of formula (I/a) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
- the invention also relates to another process for the preparation of specific compounds of formula (I/a), which are a particular case of compounds of formula (I), which uses as starting material a compound of formula (11/ A):
- compounds of formula (I/c) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
- the invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
- X 2 , X , and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO 2 alkyl,
- compounds of formula (I/b) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
- R 7 is hydrogen or (C ⁇ -C 6 )alkyl
- R" is hydrogen or (CrC 6 )alkyl
- Ri, R 2 , Gi, Xi, X 2 , X 3 , A, Y 1 ⁇ Zi, n and m have the same meaning as that defined for the compound of formula (I).
- the compounds of the invention that are present in the form of a mixture of diastereoisomers are isolated in a pure form by using conventional separation techniques such as chromatography.
- compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and more particularly inhibitors of the enzyme MMP-13.
- their use is recommended for the treatment of diseases or complaints involving a therapy by MMP-13 inhibition.
- the use of the compounds of the present invention may be recommended for the treatment of any pathology in which destruction of extracellular matrix tissue occurs, and most particularly pathologies such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.
- the present invention also relates to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), an isomer thereof, a N-oxide thereof, or an addition salt thereof with a pharmaceutically-acceptable acid or base, alone or in combination with one or more pharmaceutically-acceptable, inert, non-toxic excipients or carriers.
- compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per- or trans-cutaneous, intravaginal, rectal, nasal, perlingual, buccal, ocular or respiratory administration.
- compositions according to the invention for parenteral injections especially include aqueous and non-aqueous sterile solutions, dispersions, suspension and emulsions, and also sterile powders for reconstituting injectable solutions or dispersions.
- compositions according to the invention for oral administration in solid form especially include tablets or dragees, sublingual tablets, sachets, gelatin capsules and granules, for oral, nasal, buccal or ocular administration in liquid form, especially include emulsions, solutions, suspensions, drop, syrups and aerosols.
- compositions for rectal or vaginal administration are preferably suppositories, and those for per- or trans-cutaneous administration especially include powders, aerosols, creams, ointment, gels and patches.
- the pharmaceutical compositions mentioned hereinbefore illustrate the invention but do not limit it in any way.
- inert, non-toxic excipients or carriers there may be mentioned, by way of non-limiting example, diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrating agents, retardants, lubricants, absorbents, suspending agents, colorants, aromatizing agents etc...
- the useful dosage varies according to the age and weight of the patient, the administration route, the phannaceutical composition used, the nature and severity of the disorder and the administration of any associated treatments.
- the dosage ranges from 2 mg to 1 g per day in one or more administrations.
- the compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active principle (compound of formula (I)) and 40% to 99.5% by weight of pharmaceutically acceptable excipients or carriers.
- the starting materials used are products that are known or that are prepared according to known operating procedures.
- the various preparations yield synthetic intermediates that are useful in preparation of the compounds of the invention. Some of these intermediates are new compounds.
- aluminium chloride (5.51 g, 41.3 mmol) was added in portions to a suspension of 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate A ; 2.4 g, 6.89 mmol) in benzene (50 ml) and the mixture obtained was heated at 50°C under stirring for 2 hours.
- the mixture obtained was heated to 50°C under nitrogen atmosphere and maintained under stirring for 3 hours. After cooling, the solvent was removed under reduced pressure and the semi-solid residue obtained was stirred in a mixture of water and dichloromethane for 25 minutes.
- the solid insoluble in the 2 phases was isolated by filtration, washed with CH 2 C1 2 and dried under vacuum to afford a first portion (0.16 g) of the entitled compound.
- the organic phase was separated, washed with brine, dried over Na 2 SO 4 and evaporated to give an additional portion (0.23 g) of the desired compound
- Example 4 Evaluation of the in vitro activity of the MMP-13 inhibitor compounds according to the invention.
- the inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 is evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP-13.
- the peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester- Leu-Leu-Gly-OEt.
- the inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC 50 value, which is the concentration of inhibitor for which an inhibition of 50% of the activity of the matrix metalloprotease under consideration is observed.
- IC 50 value is the concentration of inhibitor for which an inhibition of 50% of the activity of the matrix metalloprotease under consideration is observed.
- concentrations of the inhibitory compound present in a 2.0% DMSO solution and 2.5 nM of the catalytic domain of human MMP-13 are added to the test samples.
- concentrations of inhibitors present in the test samples range from 100 ⁇ M to 0.5 nM.
- the measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbance at 405 nm using a spectrophotometer for reading microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes.
- the IC 50 values are calculated from a curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.
- the IC 50 values on MMP-13 of the compounds of Examples 1 to 3 are all below 0.1 ⁇ M.
- IC 50 values for MMP-13 which are about 100 times lower than the IC 50 values for the same compounds with respect to the other matrix metalloproteases tested.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
A compound selected from those of formula (I) wherein: X1, X2 and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, G1 represents oxygen or S(O)p in which p is from 0 to 2, G2 represents carbon-carbon triple bond, C=O, C=S, S(O)q in which q is from 0 to 2, or a group of formula (i/a) in which Y1 and Y2 are as defined in the description, n is from 0 to 6, Z1 represents CR4R5. wherein R4 and R5 are as defined in the description, A represents 5- or 6-membered monocycle or bicycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, R1 represents hydrogen, alkyl, alkenyl, alkynyl, (these groups may be optionally substituted as defined in the description) or the group of formula (i/b) in which s, Z2, B, t and G3 are as defined in the description, and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease, for the treatment of i.a arthritis and cancer.
Description
TITLE OF THE INVENTION
THIAZINE AND OXAZINE DERIVATIVES AS MMP-13 INHIBITORS FOR TREATING ARTHRITIS
FIELD OF THE INVENTION
The present invention relates to novel thiazine and oxazine derivatives which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor. These medicinal products are useful in particular for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.
TECHNOLOGICAL BACKGROUND OF THE INVENTION
Matrix metalloproteases (MMPs) are enzymes which are involved in the renewal of extracellular matrix tissue, such as cartilage, tendons and joints. MMPs bring about the destruction of the extracellular matrix tissue, which is compensated for, in a non- pathological physiological state, by its simultaneous regeneration.
Under normal physiological conditions, the activity of these extremely aggressive peptidases is controlled by specialized proteins which inhibit MMPs, such as the tissue inhibitors of metalloprotease (TLMPs).
Local equilibrium of the activities of MMPs and of TLMPs is critical for the renewal of the extracellular matrix. Modifications of this equilibrium which result in an excess of active MMPs, relative to their inhibitor, induce a pathological destruction of cartilage, which is observed in particular in rheumatoid arthritis and in osteoarthritis.
In pathological situations, an irreversible degradation of articular cartilage takes place, as is the case in rheumatic diseases such as rheumatoid arthritis or osteoarthritis. In these pathologies, the cartilage degradation process predominates, leading to a destruction of the tissue and resulting in a loss of function. At least twenty different matrix metalloproteases have been identified to date and are subdivided into four groups, the collagenases, the gelatinases, the stromelysins and the membrane-type MMPs (MT-MMPs), respectively.
Matrix metalloprotease-13 (MMP-13) is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.
There is a need in the prior art for novel MMP inhibitors, more particularly for MMP-13 inhibitors, in order to prevent and/or correct the imbalance in the renewal of extracellular matrix tissue, such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPD), age-related macular degeneration (ARMD) and cancer. MMP-inhibitor compounds are known. Most of these MMP-inhibitors are not selective for a single MMP, such as those described by Montana and Baxter (2000) or by Clark et al. (2000).
There is also a need in the prior art for novel inhibitors that are active on matrix metalloprotease-13, in order to enrich the therapeutic arsenal that can be used for treating pathologies associated with the destruction of the extracellular matrix and with cancer.
SUMMARY OF THE INVENTION
The applicant has identified novel thiazine and oxazine derivatives that are matrix metalloprotease inhibitors, and more specifically compounds that are selective MMP-13 inhibitors.
More specifically, the present invention relates to compounds of formula (I) :
• Xι, X2, and X3, independently of each other, represent a nitrogen atom or a group -CR3 in which R3 represents a group selected from hydrogen, ( -C^alkyl, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, hydroxy, ( -C6)alkoxy, and halogen,
with the proviso that not more than two of the groups Xi, X2 and X3 simultaneously represent a nitrogen atom,
• G\ represents an oxygen atom or a group S(O)p in which p represents an integer from 0 to 2 inclusive,
• G2 represents a group selected from carbon-carbon triple bond, C=O, C=S, S(O)q in which q represents an integer from 0 to 2 inclusive, or a group of formula (i/a):
• n represents an integer from 0 to 6 inclusive,
• Z\ represents -CR4R5, wherein R and R5; identical or different independently of each other, represent a group selected from hydrogen,
halogen, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino in which each alkyl moiety is identical or different, -OR6, -SR5, and -C =O)OR6, in which R6 is hydrogen atom or
(d-C6)alkyl, and
- wherein when n is greater than or equal to 2, the hydrocarbon chain Z1 optionally contains one to two isolated or conjugated multiple bonds,
- and or wherein when n is greater than or equal to 2 one of said -CR4R5 may be replaced with a group selected from oxygen, S(O)r in which r represents an integer from 0 to 2 inclusive, -NH and -N(Cι-C6)alkyl,
• A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
R\ represents a group selected from :
- hydrogen,
- (Cι-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(C1-C6)alkyl, cycloalkyl, -C(=O)NR7R8, -C(=O)OR7, OR7, and SR7, in which R7 and R8, which may be identical or different independently of each other, represent hydrogen or (Cι-C6)alky
- and the group of formula (i/b) :
■S in which s is an integer from 0 to 8 inclusive,
•f Z2 represents -CRgRto wherein R9 and R10, identical or different independently of each other, represent a group selected from hydrogen, (CrC^alkyl, phenyl, trihalogeno(Ci-C6)alkyl, halogen, amino, ORe, SR6 and -C(=O)OR6 in which Rδ is as defined hereinbefore, and
- wherein when s is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein when p is greater or equal to 2, one of said -CR9R10 may be replaced with a group selected from oxygen, S(O)u in which u is an integer from 0 to 2 inclusive, -NH, -N(C1-C6)alkyl, and carbonyl,
■S B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
•S X is an integer from 0 to 7 inclusive,
the group(s) G3, which may be identical or different independently of each other, is (are) selected from (CrC6)alkyl, halogen, CN, NO2, CF3, OCF3, -(CH2)kNRπRι2,
-N(Rπ)SO2R12, -N(SO2Ru)2, -ORu, -S(O)klRlb -SO2-N(Rπ)-(CH2)ιώ-NR12R13, -(CH2)kSO2NRπR12,
-X4(CH2)kC(=O)ORπ, -(CH2)kC(=O)ORn, -C(=O)O-(CH2)k2-NR„Rι2,
-R15-C(=O)ORu, -X5-R16, and -C(=O)-R17-NRπR12 in which :
- represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (C1-C6)alkyl group,
- k is an integer from 0 to 3 inclusive,
- kl is an integer from 0 to 2 inclusive,
- k2 is an integer from 1 to 4 inclusive,
- Rπ, R12 and R13, which may be identical or different independently of each other, are selected from hydrogen and (CrC^alkyl,
- R14 represents a group selected from (C1-C6)alkyl, -R17-NRπR12, -R17-NRπ-C(=O)-R17-NR12R13, and -C(=O)O-R17-NRnR12 in which R17 represents a linear or branched (CrC6)alkylene group, and Rπ, Rι2 and R13 are as defined hereinbefore,
- R15 represents a (C3-C6)cycloalkyl group,
- X5 represents a group selected from a single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C1-C6)alkyl,
- R16 represents a group selected from : a 5- or 6-membered monocyclic aryl or heteroaryl, which is optionally substituted by one or more groups, which may be identical or different independently of each
other, selected from (Cι-C6)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and - C(=O)OR7 wherein R represents hydrogen or ( -C^alkyl, o and a 5- or 6-membered monocyclic cycloalkyl or heterocycloalkyl, which is optionally susbstituted by one or more groups, which may be identical or different indepently of each other, selected from (CrC^alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR7 wherein R7 represents hydrogen or ( -C^alkyl,
• m is an integer from 0 to 7 inclusive,
• the group(s) R2, which may be identical or different independently of each other, is (are) selected from (CrC6)alkyl, halogen, -CN, -NO2, -SCF3, -CF3, -OCF3, -NR7R8, -OR7, -SR7, -SOR7, -SO2R7, -(CH2)kSO2NR7R8, -X7(CH2)kC(=O)OR7, -(CH2)kC(=O)OR7, -X7(CH2)kC(=O)NR7R8, -(CH2)kC(=O)NR7R8, and -X8-Rι8 in which:
X7 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C1-C6)alkyl,
- k is an integer from 0 to 3 inclusive,
- R7 and R8, which may be identical or different independently of each other, are selected from hydrogen and (CpC6)alkyl,
X8 represents a group selected from single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (d-C6)alkyl,
- R18 represents a group selected from phenyl, a 5- or 6-membered monocyclic, heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (C1-C6)alkyl, halogen, hydroxy and amino,
and optionally, their racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts, and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H- l,3-benzothiazine)-benzoate, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzothiazine and 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzothiazine.
According to a first embodiment, the invention relates to compounds of formula (I) wherein :
• Gi represents a sulphur atom, • G2 represents a group of formula (i/a):
(i a)
Y, in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Y\ represents an oxygen atom, and Y2 represents a group -NH,
• Xls X2, X3, n, Z\, A, Ri, m and R2 are as defined in formula (I).
According to a second embodiment, the invention relates to compounds of formula (I) wherein :
• G\ represents an oxygen atom,
• G2 represents a group of formula (i/a):
• Xi, X2, X3, n, Z\, A, R1; m and R2 are as defined in formula (I).
According to a third embodiment, the invention relates to compounds of formula (I) wherein : • Gt represents a sulphur atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xls X2, X3, Zi, A, R1; m and R2 are as defined in formula (I).
According to a fourth embodiment, the invention relates to compounds of formula (I) wherein :
• Gi represents an oxygen atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Zi, A, R ; m and R are as defined in formula (I).
The substituent Rt that is preferred according to the invention is the group of formula (i/b):
More particularly, the substituent R! that is preferred according to the invention is the group of formula (i/b):
More particularly, the substituent Rj that is preferred according to the invention is the group of formula (i/b):
Preferred compounds of the invention are compounds of formula (I) wherein X represents a group -CR in which R3 represents a hydrogen atom, X2 represents a nitrogen atom or a
group -CR in which R represents a hydrogen atom, and X3 represents a group -CR3 in which R3 represents a hydrogen atom.
Advantageously, preferred compounds of the invention are those compounds of formula (I) wherein Z\ represents -CR R5 in which t and R5 represent each a hydrogen atom, and n is equal to one.
Especially preferred compounds of the invention are compounds of formula (I) wherein A represents a group selected from phenyl and pyridyl, m is equal to zero or one, and R2 represents a ( -C^alkoxy group or a hydrogen atom.
Another especially preferred compounds of the invention are compound of formula (I) wherein A represents an imidazolyl group.
More particularly, the invention relates to the following compounds of formula (I) :
- 3-benzyl-254-dioxo-3,4-dihydro-2H-benzo[e][l,3]thiazine-6-carboxylic acid 4-methoxy benzylamide;
- 3-(4-methoxybenzyl)2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]oxazine-6-carboxylic acid 4-methoxybenzylamide;
- and 4- [2,4-dioxo-6-(3 -phenyl-prop- 1 -ynyl)-4H- 1 ,3 -benzothiazin-3 -ylmethyl] -benzoic acid.
The optical isomers, the N-oxides, as well as the addition salts with a pharmaceutically- acceptable acid or base, of the preferred compounds form an integral part of the invention.
The invention also relates to a pharmaceutical composition comprising as active ingredient an effective amount of a compound of formula (I) together with one or more pharmaceutically-acceptable excipients or carriers.
Another embodiment of the invention concerns the use of the compound of formula (I) for the preparation of a medicinal product intended for treating a disease involving therapy by
inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease.
The invention also relates to a method for treating a living body afflicted with a disease involving a therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease, the said method comprising the administration of an effective amount of a compound of formula (I) to a patient in need thereof.
A preferred method of treatment according to this invention is treatment of a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
More particularly, a preferred method of treatment according to this invention is treatment of disease selected from arthritis, osteoarthritis and rheumatoid arthritis.
DETAILED DESCRIPTION OF THE INVENTION
The compounds provided by this invention are those defined in formula (I). In formula (I), it is understood that :
- a (C1-C6)alkyl group denotes a linear or branched group containing from 1 to 6 carbon atoms ; example of such groups, without implying any limitation are methyl, ethyl, propyl, isopropyl, tert-butyl, neopentyl, hexyl, - a (C2-C6)alkenyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more double bonds ; examples of such groups without implying any limitation are vinyl, allyl, 3-buten-l-yl, 2-methyl-buten-l-yl, hexenyl,
- a (C2-C6)alkynyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more triple bonds ; examples of such groups without implying any limitation are ethynyl, propynyl, 3-butyn-l-yl, 2-methyl-butyn-l-yl, hexynyl,
- a (C1-C6)alkoxy group means the alkyl group as mentioned above bound through an oxygen atom ; examples of such compounds without implying any limitation are methoxy, ethoxy, n-propyloxy, tert-butyloxy,
- a mono(C1-C6)alkylamino denotes a amino group substituted by one (d-C^alkyl group as defined hereinbefore ; example of such groups, without implying any limitation are methyl amino, isobutyl amino, ethylamino, a di(C1-C6)alkylamino denotes a amino group substituted by two (C1-C6)alkyl groups as defined hereinbefore, each alkyl group being identical or different ; example of such groups, without implying any limitation are dimethylamino, diethylamino, - an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated ; examples of such groups without implying any limitation are, phenyl, naphthyl, indenyl, benzocyclobutenyl, - a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen ; examples of such groups without implying any limitation are furyl, thienyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzofuryl, benzothienyl, indolyl, quinolyl, isoquinolyl, imidazolyl, benzodioxolyl, benzodioxinyl, benzo[l,2,5]thiadiazolyl, benzo[l,2,5]oxadiazolyl,
- a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character ; examples of such groups without implying any limitation are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, adamantyl, decalinyl, norbornyl, a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen,
- a bicycle denotes two fused-monocycle or two bridged-monocycle, - a trihalogeno(C -C6)alkyl group denotes an alkyl group as defined above which contains a trihalogeno group ; examples of such groups without implying any limitation are trifluoromethyl, 2,2,2-trifluoroethyl,
a (CrC7)acyl group denotes an alkyl group or an aryl group as defined above bound through a carbonyl group ; examples of such groups without implying any limitation are acetyl, ethylcarbonyl, benzoyl, a multiple bond denotes double bond or triple bond, - a halogen atom means fluoro, chloro, bromo or iodo, optical isomers refer to racemates, enantiomers and diastereoisomers.
The invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I). A review of the pharmaceutically acceptable salts will be found in J. Pharm. Scl, 1911, 66, 1-19. Pharmaceutically acceptable acids mean non-toxic mineral or organic acids. Among those there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, nitric acid, citric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, benzoic acid, toluenesulfonic acid, etc...
Pharmaceutically acceptable bases mean non-toxic mineral or organic bases. Among those, there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, calcium hydroxide, triethylamine, tert-butylamine, dibenzylethylenediamine, piperidine, pyrrolidine, benzylamine, quaternary ammonium hydroxides etc...
The invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
to yield the compound of formula (IV) :
compound of formula (IV) in which the leaving group X is reacted with a cyanocuprate to yield the compound of formula (V) :
which compound of formula (V) is treated with an acid like sulfuric acid to yield the compound of formula (VI):
compound of formula (VI) which is treated with a compound of formula (VII): αy.-©-^ rø in which Zls R2, A, n and m have the same definitions as the compound of formula (I),
by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (I/a) which is a particular case of the compounds of formula (I):
compounds of formula (I/a) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
The invention also relates to another process for the preparation of specific compounds of formula (I/a), which are a particular case of compounds of formula (I), which uses as starting material a compound of formula (11/ A):
compound of formula (II/A) which is treated with SOCl2 to yield the compound of formula
(III/A) :
to yield the compound of formula (V/A):
compound of formula (V/A) reacting with a chloroformate compound, to yield the compound of formula (I/c) which is a particular case of the compounds of formula (I):
The invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
compound of formula (II) which is treated in basic medium with a benzylisocyanate to yield the compound of formula (VIII) :
compound of formula (VIII) which is treated with A1C13 in an apolar solvent to yield the compound of formula (IX) :
which compound of formula (LX) is treated in the presence of an inorganic base with a compound of formula (X):
in which R! is as defined in the compound of formula (I) and X' represents a leaving group like halogen atom, mesylate, tosyslate or triflate group,
to yield a compound of formula (XI) :
to yield the compound of formula (I b), which is a particular case of the compound of formula (I):
compounds of formula (I/b) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
A general process for the synthesis of the compounds of formula (I) is described in the following scheme:
in which R7 is hydrogen or (Cι-C6)alkyl, R" is hydrogen or (CrC6)alkyl, and Ri, R2, Gi, Xi, X2, X3, A, Y1} Zi, n and m have the same meaning as that defined for the compound of formula (I).
The compounds of the invention that are present in the form of a mixture of diastereoisomers are isolated in a pure form by using conventional separation techniques such as chromatography.
As mentioned above, compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and more particularly inhibitors of the enzyme MMP-13.
In this respect, their use is recommended for the treatment of diseases or complaints involving a therapy by MMP-13 inhibition. By way of example, the use of the compounds of the present invention may be recommended for the treatment of any pathology in which destruction of extracellular matrix tissue occurs, and most particularly pathologies such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.
The present invention also relates to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), an isomer thereof, a N-oxide thereof, or an addition salt thereof with a pharmaceutically-acceptable acid or base, alone or in combination with one or more pharmaceutically-acceptable, inert, non-toxic excipients or carriers.
Among the pharmaceutical compositions according to the invention, there may be mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per- or trans-cutaneous, intravaginal, rectal, nasal, perlingual, buccal, ocular or respiratory administration.
Pharmaceutical compositions according to the invention for parenteral injections especially include aqueous and non-aqueous sterile solutions, dispersions, suspension and emulsions, and also sterile powders for reconstituting injectable solutions or dispersions.
Pharmaceutical compositions according to the invention for oral administration in solid form especially include tablets or dragees, sublingual tablets, sachets, gelatin capsules and granules, for oral, nasal, buccal or ocular administration in liquid form, especially include emulsions, solutions, suspensions, drop, syrups and aerosols.
Pharmaceutical compositions for rectal or vaginal administration are preferably suppositories, and those for per- or trans-cutaneous administration especially include powders, aerosols, creams, ointment, gels and patches.
The pharmaceutical compositions mentioned hereinbefore illustrate the invention but do not limit it in any way.
Among the pharmaceutically acceptable, inert, non-toxic excipients or carriers there may be mentioned, by way of non-limiting example, diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrating agents, retardants, lubricants, absorbents, suspending agents, colorants, aromatizing agents etc...
The useful dosage varies according to the age and weight of the patient, the administration route, the phannaceutical composition used, the nature and severity of the disorder and the administration of any associated treatments. The dosage ranges from 2 mg to 1 g per day in one or more administrations. The compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active principle (compound of formula (I)) and 40% to 99.5% by weight of pharmaceutically acceptable excipients or carriers.
The examples that follow illustrate the invention but do not limit it in any way.
The starting materials used are products that are known or that are prepared according to known operating procedures. The various preparations yield synthetic intermediates that are useful in preparation of the compounds of the invention. Some of these intermediates are new compounds.
The structures of the compounds described in the Examples and Preparations were determined according to the usual spectrophotometric techniques (infrared, nuclear magnetic resonance, mass spectrometry, ...) In the Examples, it is understood that :
- DMSO means dimethylsulfoxide,
- TOTU means O-(ethoxycarbonyl)cyanomethylamino]-N-N-N'-iV'-tetramethyl uronium fluoroborate,
EXAMPLES
Intermediate A : 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione
A stirred suspension of 5-bromo-2-mercaptobenzoic acid (prepared after K. Sindelar and coll., Coll. Czech. Chem. Comm., 1988, 53 (2), 340) (8 g, 34.3 mmol) in yridine (100 ml) was treated with benzyl isocyanate (4.3 ml, 34.3 mmol) and the mixture was heated at
105°C for 7 hours under a nitrogen atmosphere. Further benzyl isocyanate was added (4.3 ml) and the mixture heated at 105°C overnight under stirring. After cooling to room temperature, water was added until precipitation and the suspension stirred for 1 hour. The resulting precipitate was collected by filtration, washed several times with water and dried under high vacuum to give 11.5g (yield : 96%) of the entitled compound as a white amorphous solid.
Intermediate B : 3-benzyl-6-cyano-3,4-dihydro-benzothiazine-2,4-dione
CuCN (0.197g, 2.2 mmol) was added to a suspension of 3-benzyl-6-bromo-3,4-dihydro- benzothiazine-2,4-dione (intennediate A ; 0.35 g, 1.22 mmol) in N-methylpyrrolidone (4 ml) and the suspension obtained was heated at reflux under stirring for 2.5 hours. The solvent was removed under reduced pressure and the sticky residue obtained was stirred in a mixture of NH4OH solution and dichloromethane. The organic phase was separated, washed with brine and dried over Na2SO4. The solvent was evaporated to afford 0.28 g of crude solid that was purified by chromatography on silica gel (cyclohexane 20/CH Cl2 80) to give the entitled compound (0.15 g ; yield : 51%) as a white solid pure in TLC
(cyclohexane 20 / CH2C1280 ; Rf = 0.40).
Intermediate C : 3-benzyI-6-carboxy-3,4-dihydro-benzothiazine-2,4-dione
A suspension of 3-benzyl-6-cyano-3,4-dihydro-benzotliiazine-2,4-dione (intermediate B ;
0.12 g, 0.4 mmol) in concentrated sulfuric acid (3 ml) and water (3 ml) was heated at reflux under stirring for 3 hours. After cooling to room temperature, water was added and the insoluble solid was collected by filtration, washed several times with water and dried
under high vacuum to give, after purification by chromatography on silica gel (CH2C12 95/methanol 5), 0.04g (yield : 31%) of the entitled compound as a white solid pure in TLC (CH2C12 90 / methanol 10 ; Rf = 0.30).
Intermediate D : 4-hydroxy-N,N'-bis[(4-methoxyphenyl)methyl]-l,3- benzenedicarboxamide
A mixture of 4-hydroxyisophthalic acid (2.0 g ; 11 mmol) in thionyl chloride (20 ml) and dimethylformamide (2 drops) was heated at reflux under stirring overnight. The excess of thionyl chloride was removed by evaporation and the residue dissolved into dichloromethane (100 ml). After cooling, 4-methoxybenzylamine (6.8 g ; 50 mmol) was added in one portion and the mixture obtained was stirred at room temperature for 1 hour. The insoluble solid was separated by filtration and purified by chromatography on silica gel (CH2C12 95/methanol 5) to give 2.0 g of the entitled compound (yield : 43%) as a white solid pure in TLC (CH2C12 90/methanol 10 ; Rf = 0.70).
Intermediate E : 6-bromo-3,4-dihydro-benzothiazine-2,4-dione
Under an inert atmosphere, aluminium chloride (5.51 g, 41.3 mmol) was added in portions to a suspension of 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate A ; 2.4 g, 6.89 mmol) in benzene (50 ml) and the mixture obtained was heated at 50°C under stirring for 2 hours. After cooling, the mixture was poured into iced water, the precipitated product was filtrated after 1 h standing, washed several times with water until neutral pH, dried and finally triturated in dichloromethane then dried under high vacuum to give 1.5 g (yield : 84%) of the entitled compound pure in TLC (CH2C12 ; Rf = 0.10). NMR H1 (DMSO) δ (ppm) : 5.5(s, 2H); 7.25-7.35 (m, 3H); 7.5 (m, 1H); 7.65 (m, 2H); 8.65 (m, 1H); 8.75 (m, 1H); 9.05 (s, 1H).
Intermediate F : t-butyl 4-(6-bromo-2,4-dioxo-4H-l,3-benzothiazin-3-ylmethyl)- benzoate
A suspension of 6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate E ; 1.5 g, 5.8 mmol) and cesium carbonate (1.89 g, 5.8 mmol) in dimethylfonnamide (20 ml) was stirred under a nitrogen atmosphere for 0.5 hour at room temperature and treated with 4-(t- butoxycarbonyl)benzyl bromide (1.57 g, 5.8 mmol) ; the mixture obtained was heated at 80°C under stirring and inert atmosphere for 2 hours. The solvent was removed under reduced pressure, and the residue was partitioned between water and dichloromethane. The aqueous layer was reextracted with CH2C12, the organic phases combined and dried over Na2SO4. The solvent was removed under reduced pressure to afford 2.4 g of crude solid that was purified by chromatography on silica gel (CH2C12) to give the entitled compound (1.95 g ; yield : 85%) as a white solid pure in TLC (CH2C1299/CH3OH 1 ; Rf = 0.70).
Intermediate G : 4-(6-bromo-2,4-dioxo-4JHr-l,3-benzothiazin-3-ylmethyl)-benzoic acid
A stined solution of 6-bromo-3-(4-t-butoxycarbonylbenzyl)-3,4-dihydro-benzothiazine- 2,4-dione (intermediate F ; 0.6 g, 1.34 mmol) in CH2C12 (60 ml) was treated at room temperature with trifluoroacetic acid (6 ml). The reaction mixture was stirred overnight at room temperature and poured into water; the resulting insoluble product was isolated by filtration, washed several times until neutral pH and dried under vacuum to afford the entitled acid (0.45 g ; yield : 86%) as a white solid pure in TLC (CH2C1295/CH3OH 5 ; Rf = 0.35).
Example 1 : 3-Benzyl-2»4-dioxo-3,4-dihydrα-2H-benzo[e][l,31thiazme-6-carboxylic acid 4-methuxy benzylamide
To a solution of 25 mg (0.08 mmol) of intermediate C in 2 ml of dimethylformamide, 10.9 mg (0.08 mmol) of 4-methoxybenzylamine and 26 mg (0.08 mmol) of TOTU were added under stirring. After external cooling with ice bath, 20 mg (0.16 mmol) of N,N-
diisopropyl-N-ethylamine were added and the yellow resulting solution was stirred overnight at room temperature. The solvent was removed under vacuum and the residual brown oil was purified by column chromatography over silica gel (dichloromethane then dichloromethane / methanol : 99.5 / 0.5) to yield 13 mg of the desired product (yield : 38%).
N.M.R (CDC13) 1H δ (ppm) : 3.8 (s, 3H) ; 4.6 (d, 2H) ; 5.35 (s, 2H) ; 6.5 (s, 1H) ; 6.9 (d, 2H) ; 7.2-7.35 (m, 5H) ; 7.4 (d, 2H) ; 7.5 (d, 2H) ; 8.15 (d, 1H) ; 8.6 (s, 1H). IR : 1649, 1543, 1514, 1406, 1284, 1253, 1231, 1185, 1145, 1030, 824, 731 cm"1 HPLC : Purity = 96%
Example 2 ; 3-Benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l53]oxazine-6-carboxyUc acid 4-methoxy benzyiamide
A cooled solution of N, N'-bis-(4-methoxybenzyl)-4-hydroxyisophthalic acid (intermediate D, 0.42 g, 1 mmol) in pyridine (5 ml) and acetonitrile (3 ml) was treated with ethyl chloroformate (0.12 g, 1.1 mmol) under stirring and the mixture was heated at 120°C for 8 hours under a nitrogen atmosphere. Further ethyl chloroformate was added (1.1 ml) and the mixture heated at 120°C overnight under stirring. After cooling to room temperature, the reaction mixture was poured into diluted hydrochloric solution and the product extracted several times with dichloromethane. The joined organic phases were washed with diluted hydrochloric solution, diluted solution of sodium hydroxide and brine successively and dried over Na2SO4. The solvent was evaporated and the residue triturated in dichloromethane; the insoluble solid is filtrated and dried to afford the entitled compound (0.32 g ; yield : 71%) as a white solid pure in TLC (CH2C1295/methanol ; Rf = 0.40). N.M.R
1H δ (ppm) : 3.7 (s, 6H); 4.4 (d, 2H); 6.8-6.9 (m, 4H); 7.25 (d, 2H); 7.3
(d, 2H); 7.5 (d, 1H); 8.25 (d, 1H); 8.5 (s, 1H); 9.25 (t, 1H). IR : 1759, 1693, 1638, 1513, 1446, 1327, 1305, 1244 cm"1 MP = 157°C HPLC : Purity = 98.5%
Example 3 ; 4-[2j4-Dioxo-6-(3-phenyl-prop-l-yαyl)-4iϊ»l,3-beuzotIιiazia-3- ylmethylj-benzoic acid
6-bromo-3-(4-carboxybenzyl)-3,4-dihydro-benzothiazine-2,4-dione (Intermediate G) (0.39 g ; 0.994 mmol) in dimethylformamide (4 ml) was stirred at room temperature under nitrogen atmosphere and N-ethyl-N,N-diisopropylamine (0.51 g, 3.97 mmol) was added ; the mixture was stirred until complete solubiiisation. At this time, 3-phenylprop-l-yne (0.16 g ; 1.39 mmol) was added followed by PdCl2(PPh3)2 (30 mg) and a catalytic amount of Cul. The mixture obtained was heated to 50°C under nitrogen atmosphere and maintained under stirring for 3 hours. After cooling, the solvent was removed under reduced pressure and the semi-solid residue obtained was stirred in a mixture of water and dichloromethane for 25 minutes. The solid insoluble in the 2 phases was isolated by filtration, washed with CH2C12 and dried under vacuum to afford a first portion (0.16 g) of the entitled compound. The organic phase was separated, washed with brine, dried over Na2SO4 and evaporated to give an additional portion (0.23 g) of the desired compound
(yield 92%).
N.M.R (DMSO-d6) 1H δ (ppm) : 3.94 (s, 2H); 5.23 (s, 2H); 7.27 (t, 1H); 7.37 (t, 2H); 7.40- 7.50 (m, 4H); 7.67 (d, 1H); 7.84-7.95 (m, 2H); 8.23 (s, 1H); 12.75-13.05 (m, 1H). IR : 1690, 1638, 1425, 1408, 1341, 1318, 1297, 1286, 1181, 1149, 913, 768, 726, 707 cm"1 MP = 240-242°C
HPLC : Purity = 98%
PHARMACOLOGICAL STUDIES OF COMPOUNDS OF THE INVENTION
Example 4 ; Evaluation of the in vitro activity of the MMP-13 inhibitor compounds according to the invention.
The inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 is evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP-13. The peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester- Leu-Leu-Gly-OEt.
The inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC50 value, which is the concentration of inhibitor for which an inhibition of 50% of the activity of the matrix metalloprotease under consideration is observed. To carry out this test, a reaction medium of 100 μl volume is prepared, containing: 50 mM of HEPES buffer, 10 mM of CaCl2 and 1 mM of 5,5'-dithiobis-(2-nitrobenzoic acid)
(DTNB), and 100 μM of substrate, the pH being adjusted to 7.0.
Increasing concentrations of the inhibitory compound present in a 2.0% DMSO solution and 2.5 nM of the catalytic domain of human MMP-13 are added to the test samples. The concentrations of inhibitors present in the test samples range from 100 μM to 0.5 nM. The measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbance at 405 nm using a spectrophotometer for reading microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes. The IC50 values are calculated from a curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.
The IC50 values on MMP-13 of the compounds of Examples 1 to 3 are all below 0.1 μM.
The test described above for the inhibition of MMP-13 was also adapted and used to determine the ability of the compounds of formula (I) to inhibit the matrix metalloproteases MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14. The results obtained show that the compounds according to the invention generally have
IC50 values for MMP-13 which are about 100 times lower than the IC50 values for the same compounds with respect to the other matrix metalloproteases tested.
Claims
1 - A compound selected from those of formula (I)
• G\ represents an oxygen atom or a group S(O)p in which p represents an integer from 0 to 2 inclusive,
• G2 represents a group selected from carbon-carbon triple bond, C=O, C=S, S(O)q in which q represents an integer from 0 to 2 inclusive, or a group of formula (i/a):
• n represents an integer from 0 to 6 inclusive,
• Zi represents -CRφRs, wherein R4 and R5ι identical or different independently of each other, represent a group selected from hydrogen, (Ci-C6)alkyl, trihalogeno(Ci-C6)alkyl, halogen, amino, mono(Cι-C6)alkylamino, di(Ci-C6)alkylamino in which each alkyl moiety
is identical or different, -ORδ, -SRβ, and -C(=O)OR6, in which R6 is hydrogen atom or (Ci-C6)alkyl, and
- wherein when n is greater than or equal to 2, the hydrocarbon chain Z\ optionally contains one to two isolated or conjugated multiple bonds, - and/or wherein when n is greater than or equal to 2 one of said -CR4R5 may be replaced with a group selected from oxygen, S(O)r in which r represents an integer from 0 to 2 inclusive, -NH and -N(d-C6)alkyl,
• A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyL these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
• Ri represents a group selected from :
- hydrogen,
- (Cι-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(Ci-C6)alkyl, cycloalkyl, -C(=O)NR7R8, -C(=O)OR7, OR7, and SR7, in which R7 and R8, which may be identical or different independently of each other, represent hydrogen or (Ci-C6)alkyl,
- and the group of formula (i/b) :
in which s is an integer from 0 to 8 inclusive,
Z2 represents -CR9R10 wherein R9 and R10, identical or different independently of each other, represent a group selected from hydrogen, (d-C6)alkyl, phenyl, trihalogeno(C1-C6)alkyl, halogen, amino, ORe, SR5 and -C(=O)ORό in which Re is as defined hereinbefore, and
- wherein when s is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein when p is greater or equal to 2, one of said -CR9R10 may be replaced with a group selected from oxygen, S(O)u in which u is an integer from 0 to 2 inclusive, -NH,
and carbonyl,
/ B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
V t is an integer from 0 to 7 inclusive,
■S the group(s) G3, which may be identical or different independently of each other, is (are) selected from (d-C6)alkyl, halogen, CN, NO2, CF3, OCF3, -(CH2)kNRπR12, -N(Rπ)C(=O)R12, -N(Rπ)C(=O)OR12, -N(Rπ)SO2R12, -N(SO2Rπ)2, -ORu,
-S(O)klRπ, -SO2-N(R11)-(CH2)k2-NR12R13, -(CH2)kSO2NRnR12,
-X4(CH2)kC(=O)OR11, -(CH2)kC(=O)ORπ, -C(=O)O-(CH2)k2-NR11Rι2,
-C(=O)O-(CH2)k2-C(=O)OR14, -X4(CH2)kC(=O)NRπRι2, -(CH2)kC(=O)NRπRι2, -Ri5-C(=O)ORπ, -X5-R16, and -C(=O)-R17-NRπR12 in which : - X4 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (d-C6)alkyl group,
- k is an integer from 0 to 3 inclusive,
- kl is an integer from 0 to 2 inclusive,
- k2 is an integer from 1 to 4 inclusive,
- Rπ, R12 and R13, which may be identical or different independently of each other, are selected from hydrogen and (Cι-C6)alkyl,
- Rι represents a group selected from (Ci-C6)alkyl, -R17-NRiiRι2, -R17-NRπ-C(=O)-RI7-NR12Rι3, and -C(=O)O-Rι7-NRπR12 in which R17 represents a
a linear or branched (Cι-C6)alkylene group, and Rll5 R12 and R13 are as defined hereinbefore,
- R15 represents a (C3-C6)cycloalkyl group,
- X5 represents a group selected from a single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (d-C6)alkyl,
- R16 represents a group selected from : o a 5- or 6-membered monocyclic aryl or heteroaryl, which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (Cj-C6)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and -
C(=O)OR7 wherein R represents hydrogen or (d-C6)alkyl, o and a 5- or 6-membered monocyclic cycloalkyl or heterocycloalkyl, which is optionally susbstituted by one or more groups, which may be identical or different indepently of each other, selected from (Ci-C6)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR7 wherein R7 represents hydrogen or (Ci-C6)alkyl,
• m is an integer from 0 to 7 inclusive,
• the group(s) R2, which may be identical or different independently of each other, is (are) selected from (C C6)alkyl, halogen, -CN, -NO2, -SCF3, -CF3, -OCF3, -NR7R8, -OR7, -SR7, -SOR7, -SO2R7, -(CH2)kSO2NR7Rs, -X7(CH2)kC(=O)OR7, -(CH2)kC(=O)OR7, -X7(CH2)kC(=O)NR7R8, -(CH2)kC(=O)NR7R8, and -X8-R18 in which:
- X7 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (d-C6)alkyl,
- k is an integer from 0 to 3 inclusive,
- R7 and R8, which may be identical or different independently of each other, are selected from hydrogen and (C1-C6)alkyl,
- X8 represents a group selected from single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (d-C6)alkyl,
- R18 represents a group selected from phenyl, a 5- or 6-membered monocyclic, heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (d-C6)alkyl, halogen, hydroxy and amino,
and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts, it being understood that :
- an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated ;
- a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen ; a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, these systems being saturated or partially unsaturated but without aromatic character ; a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen,
- and a bicycle denotes two fused-monocycle;
and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H- l,3-benzothiazine)-benzoate, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzothiazine and 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-l,3- benzothiazine.
2- A compound according to claim 1 wherein :
• G\ represents a sulphur atom,
• G2 represents a group of formula (i/a):
• Xi, X2, X3, n, Z\, A, Ri, m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
3- A compound according to claim 1 wherein :
• G\ represents an oxygen atom,
• G2 represents a group of formula (i/a):
- 2
(i a) Y 1 in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yi represents an oxygen atom, and Y2 represents a group -NH,
• X\, X2, X , n, Zj, A, R1; m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
4- A compound according to claim 1 wherein : • G\ represents a sulphur atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Zi, A, R1; m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
5- A compound according to claim 1 wherein :
• Gj represents an oxygen atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Zi, A, R1; m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
6- A compound according to claim 1 wherein R\ represents a group of formula (i b):
7- A compound according to claim 6 wherein R\ represents a group of formula (i/b):
8- A compound according to claim 7 wherein R1 represents a group of formula (i/b):
10- A compound according to claim wherein Z\ represents -CRRs in which R and R5 represent each a hydrogen atom, and n is equal to one, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
11- A compound according to claim 1 wherein A represents a group selected from phenyl and pyridyl, m is equal to zero or one, and R2 represents a (Ci-C6)alkoxy group or a hydrogen atom, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
12- A compound according to claim 1 wherein A represents an imidazolyl group, optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
13- A compound according to claim 1 selected from: - 3-benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]tlιiazine-6-carboxylic acid 4-methoxy benzylamide;
- 3-(4-methoxybenzyl)2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]oxazine-6-carboxylic acid 4-methoxybenzylamide;
- and 4-[2,4-dioxo-6-(3 -phenyl-prop- 1 -ynyι)-4H- 1 ,3-benzothiazin-3 -ylmethylj-benzoic acid.
14- A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II):
compound of formula (II) which is treated in basic medium with an isocyanate compound of formula (III):
in which Rihas the same definitions as the compound of formula (I),
to yield the compound of formula (IV) :
compound of formula (IV) in which the leaving group X is reacted with a cyanocuprate to yield the compound of formula (V) :
which compound of formula (V) is treated with an acid like sulfuric acid to yield the compound of formula (VI):
by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (I/a) which is a particular case of the compounds of formula (I):
compounds of formula (Fa) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
15- A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II) :
compound of formula (II) which is treated in basic medium with a benzylisocyanate to yield the compound of formula (VIII) :
in which X^ X2, X3, Gi, and X are as defined hereinbefore,
compound of formula (VIII) which is treated with A1C13 in an apolar solvent to yield the compound of formula (IX) :
which compound of formula (LX) is treated in the presence of an inorganic base with a compound of formula (X):
Ri-X' (X) in which Ri is as defined in the compound of formula (I) and X' represents a leaving group like halogen atom, mesylate, tosyslate or triflate group,
to yield a compound of formula (XI) :
compound of formula (XI) which is condensed, in the presence of dichlorobis(triphenylphosphine)palladium, cupper iodide and N,N'-diisopropylethylamine in dimethylformamide, on a compound of formula (XII) :
to yield the compound of formula (I/b), which is a particular case of the compound of formula (I):
compounds of formula (I/b) constitute some compounds of the invention.!, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
16- A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II/A):
compound of formula (II/A) which is treated with SOCl2 to yield the compound of formula
(HI A) :
to yield the compound of formula (V/A):
compound of formula (V/A) reacting with a chloroformate compound, to yield the compound of formula (I/c) which is a particular case of the compounds of formula (I):
17- A method for treating a living body afflicted with a disease where the inhibition of type -13 matrix metalloprotease is involved, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.
18- A method for treating a living body afflicted with a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel
disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.
19- A pharmaceutical composition comprising as active ingredient an effective amount of a compound as claimed in claim 1, alone or in combination with one or more pharmaceutically-acceptable excipients or carriers.
20- A pharmaceutical composition useful in the method of Claim 17 comprising as active ingredient an effective amount of a compound as claimed in claim 1, together with one or more pharmaceutically-acceptable excipients or carriers.
21- A pharmaceutical composition useful in the method of Claim 17 comprising as active ingredient an effective amount of a compound as claimed in claim 2, together with one or more pharmaceutically-acceptable excipients or carriers.
22- A pharmaceutical composition useful in the method of Claim 17 comprising as active ingredient an effective amount of a compound as claimed in claim 4, together with one or more pharmaceutically-acceptable excipients or carriers.
23- Use of a compound according to Claim 1, for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of type- 13 matrix metalloproteases .
24- Use according to Claim 23, characterized in that the disease is arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers.
25- Use according to Claim 24, characterized in that the disease is arthritis.
- Use according to Claim 24, characterized in that the disease is osteoarthritis.
- Use according to Claim 24, characterized in that the disease is rheumatoid arthritis.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002333256A AU2002333256A1 (en) | 2002-06-25 | 2002-06-25 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| PCT/EP2002/008062 WO2004000321A1 (en) | 2002-06-25 | 2002-06-25 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| EP03760686A EP1539176A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| PCT/EP2003/006601 WO2004000322A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| JP2004514844A JP2005538965A (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as MMP-13 inhibitors for the treatment of arthritis |
| US10/602,160 US20040006077A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| CA002491210A CA2491210A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| MXPA05000004A MXPA05000004A (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis. |
| BR0312107-0A BR0312107A (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for the treatment of arthritis |
| AU2003246574A AU2003246574A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/008062 WO2004000321A1 (en) | 2002-06-25 | 2002-06-25 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2004000321A1 true WO2004000321A1 (en) | 2003-12-31 |
Family
ID=29797117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/008062 WO2004000321A1 (en) | 2002-06-25 | 2002-06-25 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
| PCT/EP2003/006601 WO2004000322A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/006601 WO2004000322A1 (en) | 2002-06-25 | 2003-06-24 | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2005538965A (en) |
| AU (2) | AU2002333256A1 (en) |
| BR (1) | BR0312107A (en) |
| CA (1) | CA2491210A1 (en) |
| MX (1) | MXPA05000004A (en) |
| WO (2) | WO2004000321A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112159347A (en) * | 2020-10-27 | 2021-01-01 | 常州工程职业技术学院 | Preparation method of picolitamide |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| MXPA05001783A (en) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors. |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| BR0313384A (en) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Chromone derivatives as matrix metalloproteinase inhibitors |
| WO2004014923A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| EP1537098A1 (en) | 2002-08-13 | 2005-06-08 | Warner-Lambert Company LLC | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| EP1539709A1 (en) | 2002-08-13 | 2005-06-15 | Warner-Lambert Company LLC | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140532A (en) * | 1976-12-17 | 1979-02-20 | Fuji Photo Film Co., Ltd. | Thermally developable light-sensitive material |
-
2002
- 2002-06-25 WO PCT/EP2002/008062 patent/WO2004000321A1/en not_active Application Discontinuation
- 2002-06-25 AU AU2002333256A patent/AU2002333256A1/en not_active Abandoned
-
2003
- 2003-06-24 BR BR0312107-0A patent/BR0312107A/en not_active IP Right Cessation
- 2003-06-24 AU AU2003246574A patent/AU2003246574A1/en not_active Abandoned
- 2003-06-24 WO PCT/EP2003/006601 patent/WO2004000322A1/en not_active Application Discontinuation
- 2003-06-24 CA CA002491210A patent/CA2491210A1/en not_active Abandoned
- 2003-06-24 JP JP2004514844A patent/JP2005538965A/en active Pending
- 2003-06-24 MX MXPA05000004A patent/MXPA05000004A/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140532A (en) * | 1976-12-17 | 1979-02-20 | Fuji Photo Film Co., Ltd. | Thermally developable light-sensitive material |
Non-Patent Citations (2)
| Title |
|---|
| CHOLLET ET AL.: "Solid-phase synthesis of alpha-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 10, no. 3, 2002, pages 531 - 544, XP002224266 * |
| MONTANA J ET AL: "THE DESIGN OF SELECTIVE NON-SUBSTRATE-BASED MATRIX METALLOPROTEINASE INHIBITORS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, 2000, pages 353 - 361, XP000984034, ISSN: 1367-6733 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112159347A (en) * | 2020-10-27 | 2021-01-01 | 常州工程职业技术学院 | Preparation method of picolitamide |
| CN112159347B (en) * | 2020-10-27 | 2022-06-07 | 常州工程职业技术学院 | The preparation method of picotamide |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0312107A (en) | 2005-03-29 |
| WO2004000322A1 (en) | 2003-12-31 |
| AU2002333256A1 (en) | 2004-01-06 |
| JP2005538965A (en) | 2005-12-22 |
| CA2491210A1 (en) | 2003-12-31 |
| AU2003246574A1 (en) | 2004-01-06 |
| MXPA05000004A (en) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040006077A1 (en) | Thiazine and oxazine derivatives as MMP-13 inhibitors | |
| EP0471236B1 (en) | Imidazopyridine derivatives and their use | |
| US20030216402A1 (en) | Oxo-azabicyclic compounds | |
| US6747147B2 (en) | Oxo-azabicyclic compounds | |
| EP0873329B1 (en) | Novel n-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands | |
| US6962922B2 (en) | Alkynylated quinazoline compounds | |
| KR100248700B1 (en) | Pyrazolopyridine compound and processes for preparation thereof | |
| JP2005526070A (en) | Oxo-azabicyclic compounds | |
| WO2004000321A1 (en) | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis | |
| US20050245548A1 (en) | Alkynylated fused ring pyrimidine compounds | |
| JPH10510536A (en) | 2-Substituted 1,2,5-thiadiazolidine-3-one 1,1-dioxides and compositions thereof | |
| IL173305A (en) | Matrix metalloproteinase inhibitors, their use in preparation of medicaments, pharmaceutical compositions comprising them and methods of preparation thereof | |
| AU2004276128B2 (en) | Amide-type carboxamide derivatives | |
| KR100251522B1 (en) | Pyrrole [3,2-c] quinoline derivatives containing haloalkoxy groups and pharmaceutically acceptable salts thereof | |
| FR2613717A1 (en) | PYRIMIDINECARBOXYLIC ACID DERIVATIVES WITH THERAPEUTIC ACTION | |
| JP2003212837A (en) | Amidine derivative, anticoagulant agent given by using the same, and remedy for thrombosis | |
| CN109134481A (en) | A kind of substituted azole chromogen ketone compounds or its pharmaceutically acceptable salt and its preparation method and application | |
| EP0315112B1 (en) | Novel amide compounds | |
| EP1539176A1 (en) | Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis | |
| EP0934257B1 (en) | Substituted n-arylmethylamino derivatives of cyclobutene-3,4-diones | |
| HU202506B (en) | Process for producing benzoxazolone derivatives | |
| US7476759B2 (en) | Matrix metalloproteinase inhibitors | |
| WO1994003439A1 (en) | Antiproliferative tricyclic compounds | |
| EP0702952B1 (en) | Benzopyran derivatives | |
| JPH0581589B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |